Cargando…
Inhibition of Shp2 suppresses mutant EGFR-induced lung tumors in transgenic mouse model of lung adenocarcinoma
Epidermal growth factor receptor (EGFR) mutants drive lung tumorigenesis and are targeted for therapy. However, resistance to EGFR inhibitors has been observed, in which the mutant EGFR remains active. Thus, it is important to uncover mediators of EGFR mutant-driven lung tumors to develop new treatm...
Autores principales: | Schneeberger, Valentina E., Ren, Yuan, Luetteke, Noreen, Huang, Qingling, Chen, Liwei, Lawrence, Harshani R., Lawrence, Nicholas J., Haura, Eric B., Koomen, John M., Coppola, Domenico, Wu, Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4467431/ https://www.ncbi.nlm.nih.gov/pubmed/25730908 |
Ejemplares similares
-
ILK and SHP2 expression identify a poor prognostic cohort of EGFR-mutant lung cancer
por: Della Corte, Carminia Maria, et al.
Publicado: (2018) -
Selective inhibition of leukemia-associated SHP2(E69K) mutant by the allosteric SHP2 inhibitor SHP099
por: Sun, X, et al.
Publicado: (2018) -
EGFR-Mutant Lung Adenocarcinoma Mimicking a Pneumonia
por: Taus, Álvaro, et al.
Publicado: (2012) -
Outcomes of salvage lung resections in advanced
EGFR
‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021) -
SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness
por: Xia, Leiming, et al.
Publicado: (2021)